Literature DB >> 1774468

The importance of route of infection in determining the extent of exacerbation of listeriosis by anti-interferon-gamma monoclonal antibody.

P L Dunn1, R J North.   

Abstract

Treating mice with a neutralizing rat monoclonal antibody (mAb) against murine interferon-gamma (IFN-gamma) prevented them from controlling an otherwise sublethal Listeria infection initiated via an extravascular route, but not via an intravenous route. In mice inoculated extravascularly, anti-IFN-gamma mAb treatment caused rapid uncontrolled growth of Listeria at the site of inoculation, and the continuous systemic dissemination of large numbers of bacteria to the liver and spleen. The infection-enhancing effects of anti-IFN-gamma treatment in mice infected intravenously was seen as an increase in the number of bacteria in the liver and spleen, but in subsequent control and eventual resolution of infection beginning 5 days after inoculation. The results serve to show that the exacerbating effect of anti-IFN-gamma treatment on murine listeriosis is greater for infections initiated at extravascular sites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774468     DOI: 10.1089/jir.1991.11.291

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  3 in total

1.  Role of gamma interferon in the host immune and inflammatory responses to Pneumocystis carinii infection.

Authors:  B A Garvy; R A Ezekowitz; A G Harmsen
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

2.  Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection.

Authors:  W Chen; E A Havell; A G Harmsen
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

3.  Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes.

Authors:  J W Conlan; R J North
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.